Bioamber (BIOA) Getting Somewhat Positive News Coverage, Report Shows
News articles about Bioamber (NYSE:BIOA) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioamber earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.5542737086772 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Zacks: Analysts Set $6.50 Price Target for Bioamber Inc (BIOA) (americanbankingnews.com)
- Analyzing Analysts’ Recommendations – BioAmber Inc. (NYSE: BIOA) – The Investor Guide (wallstreetnews24.com)
- Bioamber (BIOA) & AdvanSix (ASIX) Critical Analysis (americanbankingnews.com)
- Bioamber (BIOA) Raised to Hold at Zacks Investment Research (americanbankingnews.com)
Shares of Bioamber (NYSE BIOA) traded down $0.01 during trading on Friday, reaching $0.43. 875,316 shares of the company’s stock were exchanged, compared to its average volume of 794,143. The firm has a market capitalization of $22.31, a P/E ratio of -0.61 and a beta of 2.65. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.08 and a quick ratio of 0.75. Bioamber has a 12-month low of $0.32 and a 12-month high of $5.93.
Several equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Bioamber from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Bioamber in a research note on Wednesday, November 8th. ValuEngine downgraded shares of Bioamber from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, Cowen restated a “hold” rating and issued a $1.00 price target on shares of Bioamber in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $6.50.
ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/bioamber-bioa-getting-somewhat-positive-news-coverage-report-shows/1807219.html.
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with Analyst Ratings Network's FREE daily email newsletter.